Clinical Trial

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the tolerability,safety and efficacy of OPC-415 in patients with relapsed and/or refractory Multiple Myeloma (MM).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2020-11-24; most recent amendment 2025-05-22.
Status change: Recruiting → Active, Not Recruiting 2025-05-20
Status change: Not Yet Recruiting → Recruiting 2020-12-24
Trial Details
NCT Number NCT04649073
Lead Sponsor Otsuka Pharmaceutical Co., Ltd.
Conditions Multiple Myeloma (MM)
Enrollment 11 participants
Start Date 2021-02-18
Primary Completion 2025-04-09 (estimated)
Study Completion 2041-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-25